Quantum Mechanical Assessment of Nitrosamine Potency
Chemical Research in Toxicology · 2024
DOI: 10.1021/acs.chemrestox.4c00087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2024. Verfasst von Sriman De und 5 weiteren Autor:innen. Beteiligte Einrichtung: Synthetic Molecule Design and Development, Eli Lilly Services India Pvt Ltd, Devarabeesanahalli , Bengaluru 560103, India. Hauptthemen laut MEDLINE: Nitrosamines, Quantum Theory. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Nitrosamines are in the cohort of concern (CoC) as determined by regulatory guidance. CoC compounds are considered highly potent carcinogens that need to be limited below the threshold of toxicological concern, 1.5 μg/day. Nitrosamines like NDMA and NDEA require strict control, while novel nitrosamine drug substance-related impurities (NDSRIs) may or may not be characterized as potent carcinogens. A risk assessment based on the structural features of NDSRIs is important in order to predict potency because they lack substance-specific carcinogenicity. Herein, we present a quantum mechanical (QM)-based analysis on structurally diverse sets of nitrosamines to better understand how structure influences the reactivity that could result in carcinogenicity. We describe the potency trend through activation energies corresponding to α-hydroxylation, aldehyde formation, diazonium intermediate formation, reaction with DNA base, and hydrolysis reactions, and other probable metabolic pathways associated with the carcinogenicity of nitrosamines. We evaluated activation energies for selected cases such as N-nitroso pyrrolidines, N-nitroso piperidines, N-nitroso piperazines, N-nitroso morpholines, N-nitroso thiomorpholine, N-methyl nitroso aromatic, fluorine-substituted nitrosamines, and substituted aliphatic nitrosamines. We compare these results to the recent framework of the carcinogenic potency characterization approach (CPCA) proposed by health authorities which is meant to give guidance on acceptable intakes (AI) for NDSRIs lacking substance-specific carcinogenicity data. We show examples where QM modeling and CPCA are aligned and examples where CPCA both underestimates and overestimates the AI. In cases where CPCA predicts high potency for NDSRIs, QM modeling can help better estimate an AI. Our results suggest that a combined mechanistic understanding of α-hydroxylation, aldehyde formation, hydrolysis, and reaction with DNA bases could help identify the structural features that underpin the potency of nitrosamines. We anticipate this work will be a valuable addition to the CPCA and provide a more analytical way to estimate AI for novel NDSRIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Synthetic Molecule Design and Development, Eli Lilly Services India Pvt Ltd, Devarabeesanahalli , Bengaluru 560103, India.
- Discovery Chemistry Research and Technology, LRL, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
- Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
- Toxicology, LRL, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.
ORCID-Profile: Fareed Bhasha Sayyed, Scott A Frank, Paul D Cornwell, Robert A Jolly
Zitieren
APA
De, S., Thapa, B., Sayyed, F. B., Frank, S. A., Cornwell, P. D., & Jolly, R. A. (2024). Quantum Mechanical Assessment of Nitrosamine Potency. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.4c00087
Vancouver
De S, Thapa B, Sayyed FB, Frank SA, Cornwell PD, Jolly RA. Quantum Mechanical Assessment of Nitrosamine Potency. Chemical Research in Toxicology. 2024. doi:10.1021/acs.chemrestox.4c00087
BibTeX
@article{De2024,
author = {De, Sriman and Thapa, Bishnu and Sayyed, Fareed Bhasha and Frank, Scott A and Cornwell, Paul D and Jolly, Robert A},
title = {Quantum Mechanical Assessment of Nitrosamine Potency},
journal = {Chemical Research in Toxicology},
year = {2024},
doi = {10.1021/acs.chemrestox.4c00087}
}
EUVIMED